Liothyronine (T3)

What is Liothyronine?

Liothyronine sodium is a synthetic form of triiodothyronine (T3), the biologically active thyroid hormone that directly regulates cellular metabolism, energy production, and gene expression throughout the body. Unlike levothyroxine (T4), which serves as a prohormone requiring conversion to T3 in peripheral tissues, liothyronine provides direct T3 replacement without the need for enzymatic conversion. It is approximately 4-5 times more potent than levothyroxine on a microgram-per-microgram basis.

Liothyronine is sold under the brand name Cytomel and is available as an oral tablet in strengths of 5 mcg, 25 mcg, and 50 mcg. It was originally approved by the FDA for the treatment of hypothyroidism and has been in clinical use for decades. The medication is also available as an intravenous formulation (Triostat) for the treatment of myxedema coma, a life-threatening emergency. Compounding pharmacies also prepare sustained-release T3 formulations, though these are not FDA-approved.

Liothyronine is used clinically for hypothyroidism (as monotherapy or in combination with levothyroxine), myxedema coma, thyroid suppression testing, and as short-term preparation for radioactive iodine therapy in thyroid cancer patients. Off-label, it is used in the bodybuilding community for its metabolic-enhancing effects and by some physicians as part of T3/T4 combination therapy for patients who do not feel optimized on levothyroxine alone. Its faster onset of action and shorter half-life compared to levothyroxine make it a useful therapeutic option in specific clinical scenarios.

Clinical Research & Evidence

The role of liothyronine in thyroid hormone replacement has been studied extensively, particularly in the context of combination T3/T4 therapy versus levothyroxine monotherapy. Several randomized controlled trials have investigated whether adding T3 to T4 improves quality of life, cognitive function, and metabolic outcomes in hypothyroid patients. While the results have been mixed, some studies suggest that a subset of patients, particularly those with the DIO2 polymorphism (Thr92Ala variant affecting T4-to-T3 conversion), may experience meaningful improvement with combination therapy.

Research published in the Journal of Clinical Endocrinology & Metabolism has explored patient preference for combination therapy, finding that a significant percentage of patients report subjective improvement in well-being, energy, and cognitive function when T3 is added to their regimen. However, the European Thyroid Association guidelines and American Thyroid Association guidelines note that the evidence base does not yet support universal recommendation of combination therapy, though they acknowledge it as a reasonable option for patients with persistent symptoms on levothyroxine monotherapy.

In the context of myxedema coma, research supports the use of intravenous liothyronine as part of aggressive thyroid hormone replacement, as the direct delivery of active T3 bypasses the impaired peripheral conversion that may occur in critically ill patients. Studies indicate that T3 administration in myxedema coma can produce measurable clinical improvement within hours compared to the days required for T4 alone.

Regarding off-label metabolic enhancement, limited clinical research exists. Studies in obese euthyroid subjects have not demonstrated significant long-term weight loss benefits from supraphysiologic T3 doses, and the risks of cardiac complications and muscle wasting at high doses outweigh potential benefits. Research consistently indicates that thyroid hormone should not be used as a weight-loss agent in euthyroid individuals.

Potential Benefits

• Direct T3 Replacement: Provides the biologically active thyroid hormone directly, bypassing the need for T4-to-T3 conversion, which may be impaired in some patients.
• Rapid Onset of Action: Clinical effects may be noticed within hours to days, compared to weeks with levothyroxine, making it useful in acute settings.
• Combination Therapy Option: Research suggests some patients with persistent hypothyroid symptoms on T4 alone may benefit from adding low-dose T3.
• Myxedema Coma Treatment: FDA-approved (IV formulation) for the emergency treatment of myxedema coma, where rapid thyroid hormone replacement is critical.
• Thyroid Cancer Preparation: Used for short-term preparation before radioactive iodine therapy; its short half-life allows rapid washout compared to levothyroxine.
• Improved Energy and Cognition: Some studies suggest patients may experience improved energy levels, mental clarity, and mood with optimized T3 levels.
• Metabolic Enhancement: At physiologic doses, helps regulate basal metabolic rate, body temperature, and energy expenditure.
• DIO2 Polymorphism Patients: Research indicates patients carrying the DIO2 Thr92Ala variant may particularly benefit from direct T3 supplementation.

Dosing Protocol

Note: Due to its shorter half-life and more rapid onset compared to T4, liothyronine dosing requires careful titration. When used in combination with levothyroxine, the T4 dose should be reduced (typically by 25-50 mcg for each 5-10 mcg of T3 added) to avoid over-replacement. Split dosing (morning and afternoon) may provide more stable T3 levels throughout the day. Sustained-release T3 formulations from compounding pharmacies may also be used to provide more consistent blood levels.

Reconstitution Guide

Oral liothyronine (Cytomel) is supplied as a pre-formed tablet and requires no reconstitution or preparation. The tablet is taken whole with water. For precise microdosing, tablets may be scored and split (the 25 mcg tablet has a score line). Some patients use a pill cutter for accurate splitting.

The intravenous formulation (Triostat, 10 mcg/mL) is supplied as a ready-to-use solution for injection and does not require reconstitution. It should be administered as a direct IV injection by healthcare professionals in an emergency setting. Compounded sustained-release T3 capsules are prepared by specialty compounding pharmacies and are ready to take as provided. No patient preparation is needed for any oral formulation.

Half-Life & Pharmacokinetics

Liothyronine has an elimination half-life of approximately 2.5 days (roughly 60 hours), which is substantially shorter than levothyroxine's half-life of 6-7 days. However, the clinical effects of T3 fluctuate more rapidly due to its direct receptor binding activity. After oral administration, peak serum T3 levels occur within 2-4 hours, with levels declining over the subsequent 24 hours. This peak-trough pattern is one reason why split dosing (twice daily) is sometimes recommended to maintain more stable levels.

Oral bioavailability of liothyronine is approximately 95%, which is higher than levothyroxine and less affected by food and concurrent medications. Unlike T4, which is >99% protein-bound, T3 is approximately 99.7% protein-bound but has a higher free fraction, contributing to its greater biological activity. Liothyronine is metabolized primarily through deiodination in the liver and kidneys, conjugation with glucuronide and sulfate, and excretion in bile and urine. At steady state with once-daily dosing, serum T3 levels will show notable fluctuations, which may contribute to symptoms in some patients. Sustained-release formulations aim to mitigate this pharmacokinetic challenge.

Administration Guide

Liothyronine is administered orally as a tablet. Follow these guidelines for optimal use:

• Take on an empty stomach for most consistent absorption, ideally 30-60 minutes before food
• T3 absorption is less affected by food compared to T4, but consistency in timing is still recommended
• If prescribed twice daily, take the first dose in the morning and the second dose in the early afternoon (avoid evening doses to prevent insomnia)
• Swallow tablets whole with water; tablets may be split along the score line if needed for dose adjustment
• If using in combination with levothyroxine, the T3 and T4 can be taken at the same time
• For thyroid cancer patients preparing for RAI: begin T3 after stopping T4 and discontinue T3 two weeks before the radioiodine scan or treatment
• If switching from T4 monotherapy to T3/T4 combination, the transition should be guided by your provider with appropriate T4 dose reduction
• Monitor for signs of over-replacement: palpitations, tremor, anxiety, insomnia, and weight loss may indicate the dose is too high

Side Effects & Safety

Side effects of liothyronine are primarily related to over-replacement and the peak-trough fluctuations in T3 levels. Because T3 is more potent and faster-acting than T4, the margin for error is narrower:

• Heart palpitations / tachycardia (the most concerning side effect; may occur at peak T3 levels)
• Tremor (fine hand tremor, especially at higher doses)
• Anxiety and nervousness (dose-dependent; reduce dose if persistent)
• Insomnia (especially if taken too late in the day)
• Heat intolerance and sweating
• Weight loss (may be excessive at supraphysiologic doses)
• Diarrhea / increased bowel movements
• Headache
• Muscle weakness / cramps (with prolonged supraphysiologic dosing)
• Bone density loss (with chronic over-replacement; particularly in postmenopausal women)
• Atrial fibrillation (increased risk with over-replacement, especially in elderly patients)

Stacking & Interactions

Liothyronine has fewer absorption-related drug interactions than levothyroxine but shares similar pharmacodynamic interactions due to its effects on metabolism and cardiac function. Monitor closely when adding or adjusting any concurrent medications, particularly anticoagulants and diabetes medications.

Storage & Handling

• Temperature: Store at controlled room temperature (20-25°C / 68-77°F)
• Light: Protect from light; keep in original container
• Moisture: Protect from moisture; keep container tightly closed
• IV formulation (Triostat): Refrigerate at 2-8°C; protect from light; use immediately after opening
• Compounded SR T3: Follow the compounding pharmacy's specific storage instructions; typically room temperature
• Travel: Stable at room temperature; carry in original labeled container
• Shelf life: Follow the expiration date on the packaging; typically 2-3 years from manufacture

Legal & Regulatory Status

Liothyronine sodium is an FDA-approved prescription medication (brand name Cytomel for oral tablets, Triostat for IV formulation). It is approved for the treatment of hypothyroidism, myxedema coma (IV), and as a diagnostic agent for thyroid suppression testing. Its use in T3/T4 combination therapy for hypothyroidism and for metabolic enhancement in bodybuilding contexts is considered off-label.

Liothyronine is not a DEA-controlled substance. It requires a valid prescription from a licensed healthcare provider. Generic oral formulations are available, though availability may be more limited than levothyroxine generics. Compounded sustained-release T3 preparations are available from specialty compounding pharmacies with a prescription but are not FDA-approved products. In competitive sports, thyroid hormones are not explicitly prohibited by WADA but may be subject to inquiry if detected. Always check current anti-doping regulations if participating in sanctioned competition.

Recommended Bloodwork & Monitoring

Monitoring is essential when using liothyronine, particularly due to its more dynamic pharmacokinetic profile compared to levothyroxine:

• TSH: Primary monitoring test. May be suppressed even at appropriate T3 doses due to T3's direct pituitary effects. Interpret in context of symptoms and free hormone levels.
• Free T3: Essential when using liothyronine. Draw blood 8-12 hours after the last T3 dose (trough level) for the most clinically meaningful result. Peak levels (2-4 hours post-dose) will be significantly higher.
• Free T4: Will decrease when adding T3 or if T4 dose is reduced; low free T4 with normal free T3 and suppressed TSH is expected in combination therapy.
• Reverse T3 (rT3): Some practitioners monitor this to assess T4-to-T3 conversion; not universally recommended but may inform treatment decisions.
• Heart Rate / ECG: Monitor heart rate regularly; obtain ECG if palpitations or arrhythmias are reported, particularly in patients over 50 or with cardiac history.
• DEXA Scan: Consider bone density monitoring in patients on long-term T3 therapy, especially postmenopausal women.
• Lipid Panel: Thyroid hormone levels affect cholesterol metabolism; reassess after dose stabilization.
• Blood Glucose: Monitor in diabetic patients, as T3 may increase insulin requirements.

Frequently Asked Questions

Related Compounds